Leveraging MRD to Provide High-Definition Insights for Clinical Trials
Time: 9:10 am
day: Day 1 AM
Details:
Through the recent acquisition of Haystack Oncology, Quest Diagnostics aims to combine its expertise in oncology, genomics, and pathology with Haystack's next generation liquid biopsy technology. This collaboration will drive the development of reliable MRD tests and expand their accessibility for a range of cancer types, including colorectal, breast, and lung cancers. ctDNA analysis has the potential to provide high-definition insights in drug development. Learn how you can:
- Stratify patients for trials
- Identify therapy response and resistance
- Quantifiably track variants
- Assess treatment outcome early
